Investigation of Anti Fatigue Drugs in Aircrews

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031407

Enrollment

Unknown

Registered

2020-03-30

Start date

2020-05-01

Completion date

Unknown

Last updated

2020-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fatigue

Interventions

Experimental Group:Modafinil or zaleplon

Control Group:placebo

Eligibility

Sex/Gender

Male

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Ages 18-40 years, regardless of gender; 2.Healthy objects; 3. Exerciser in air force characteristic medical centeror or social health youth; 4. Volunteers have signed informed consent.

Exclusion criteria

Exclusion criteria: 1.With history of drug allergy; 2. With Bronchial asthma; 3. With abnormal liver and kidney function and Blood Routine Indexes; 4. Abnormal ECG results (ST-T changes, frequent premature beats, etc.) 5. Previous abnormal results of color Doppler echocardiography (mitral valve prolapse, etc.) 6. Other situations that can not withstand special aviation environment such as hypoxia, overload and low air pressure.

Design outcomes

Primary

Measure	Time frame
Hypobaric hypoxia tolerance;+Gz tolerance;Vestibular function;after-effect;	—

Countries

China

Contacts

Public ContactXue Junhui

Air Force Medical University

xuejunhui@fmmu.edu.cn+86 13572273244

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026